Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial
B.J. Rimel, Angeles Alvarez Secord, Melissa A. Geller, David S. Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza, Mihaela Cristea, Jonathan S. Berek, John K. Chan, Daniela Matei, Y. Li, Ke Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk, Kathleen N. Moore
Topics & Concepts
MedicinePARP inhibitorInternal medicineAdverse effectOvarian cancerOncologyClinical trialCancerPoly ADP ribose polymeraseSurgeryPolymeraseChemistryBiochemistryGenePARP inhibition in cancer therapyAdvancements in Semiconductor Devices and Circuit DesignIntegrated Circuits and Semiconductor Failure Analysis